[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology].
Fundamental and clinical studies on imipenem/cilastatin sodium (MK-0787/MK-0791) in the field of obstetrics and gynecology were carried out. The concentration of MK-0787 in uterine tissue was 5.9-12.2 micrograms/g at 30 minutes after an administration of 500 mg/500 mg of MK-0787/MK-0791 by a 30-minute intravenous drip infusion and 0.9-1.1 micrograms/g at 185 minutes. The clinical application of the drug to 9 patients with gynecological infections produced "good" results with all the patients clearly showing clinical or bacteriological improvement. Neither side effects nor abnormal laboratory findings were observed. Based on these findings, MK-0787/MK-0791 appeared to be a useful antibiotic for the treatment obstetrical and gynecological infections.
Iwase
H
H
Seto
H
H
Hogaki
M
M
Arai
K
K
D000290:Adnexa Uteri / Q000378:metabolism; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000378:metabolism; D004338:Drug Combinations; D005187:Fallopian Tubes / Q000378:metabolism; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D015378:Imipenem; D008875:Middle Aged; D010053:Ovary / Q000378:metabolism; D013845:Thienamycins / Q000008:administration & dosage* / Q000378:metabolism; D014599:Uterus / Q000378:metabolism
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem